Xtant Medical Holdings, Inc. (XTNT) Stock Score, Valuation & Financial Research
Xtant Medical Holdings, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for XTNT
Xtant Medical Holdings, Inc. currently has a Wall Street Score of 26/100. The stored market price is $0.33. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Xtant Medical Holdings, Inc. does
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extre
XTNT financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $0.33
- Market capitalization:
- $45.8M
- Revenue:
- $109.5M
- Net income:
- $-11.1M
- Free cash flow:
- $10.2M
- Cash:
- $9.9M
- Total debt:
- $26.0M
- EPS:
- -0.08
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 37/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $10.2M, showing positive cash generation.
- The balance sheet shows $9.9M of cash versus $26.0M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research XTNT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.